Fig 5. Inhibiting HSPB1-mediated G6PD activation attenuates the chemo-resistance of glioma cells.

(A-B) U87 cells were transfected with siRNAs against G6PD and/or HSPB1 as indicated. Cells were treated with TMZ (A) or MNNG (B), cell viability was determined. (C) U373 cells were transfected with siRNAs against G6PD and/or HSPB1 as indicated. Cells were treated with MNNG, cell viability was determined.(D-E) U87 cells were transfected with siRNAs against G6PD and/or HSPB1 as indicated. Cells were treated with H₂O₂ (D) or diamide (E), cell viability was determined. (F) U373 cells were transfected with siRNAs against G6PD and/or HSPB1 as indicated. Cells were treated with diamide, cell viability was determined. (G-H) Kaplan-Meier survival curves for TCGA glioblastoma multiforme (G) and brain lower grade glioma (H) study. The patients were stratified by median HSPB1 levels (‘high’ is greater than median, ‘low’ is less than or equal to median).